Chinese guidelines for the diagnosis and treatment of heart failure 2014

Chinese Journal of Cardiology

Volumn 42, Issue 2, 2014, Pages 98-122

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHINESE MEDICINE; HEART FAILURE; PRACTICE GUIDELINE;

CHINA; HEART FAILURE; HUMANS;

EID: 84896486149     PISSN: 02533758     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3758.2014.02.004     Document Type: Article

References (146)

1. 2002, 30: 450-454.
2. McMurray J J. Clinical practice. Systolic heart failure[J]. N Engl J Med, 2010, 362: 228-238.
3. Shah A M, Mann D L. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science[J]. Lancet, 2011, 378: 704-712.
4. Hunt S A, Abraham W T, Chin M H, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): 2005, 112: e154-e235.
5. 2007, 35: 1076-1095.
6. 2010, 38: 195-208.
7. Jessup M, Abraham W T, Casey D E, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation[J]. Circulation, 2009, 119: 1977-2016.
8. Dunlay S M, Redfield M M, Weston S A, et al. Hospitalizations after heart failure diagnosis a community perspective[J]. J Am Coll Cardiol, 2009, 54: 1695-1702.
9. Troughton R W, Frampton C M, Yandle T G, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations[J]. Lancet, 2000, 355: 1126-1130.
10. Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial[J]. JAMA, 2009, 301: 383-392.
11. Lainchbury J G, Troughton R W, Strangman K M, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-assisted treatment to lessen serial cardiac readmissions and death) trial[J]. J Am Coll Cardiol, 2009, 55: 53-60.
12. Porapakkham P, Porapakkham P, Zimmet H, et al. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis[J]. Arch Intern Med, 2010, 170: 507-514.
13. Lainchbury J G, Troughton R W, Strangman K M, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-assisted treatment to lessen serial cardiac' readmissions and death) trial[J]. J Am Coll Cardiol, 2009, 55: 53-60.
14. Savarese G, Trimarco B, Dellegrottaglie S, et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2, 686 patients in 12 randomized trials[J]. PLoS One, 2013, 8: e58287.
15. Jang J S, Jin H Y, Seo J S, et al. The role of brain natriuretic peptide-guided heart failure therapy: an updated meta-analysis[J/OL]. J Am Coll Cardiol, 2013: 61(10_S): E743 [2013-08-05]. http://content.onlinejacc.org/article ID: 1665054. [published online ahead of print March 12.2013].
16. Anand I S, Florea V G, Fisher L. Surrogate end points in heart failure[J]. J Am Coll Cardiol, 2002, 39: 1414-1421.
17. McHorney C A, Ware JE Jr, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs[J]. Med Care, 1993, 31: 247-263.
18. Alia F, Brianison S, Guillemin F, et al. Self-rating of quality of life provides additional prognostic information in heart failure. Insights into the EPICAL study[J]. Eur J Heart Fail, 2002, 4: 337-343.
19. Green C P, Porter C B, Bresnahan D R, et al. Development and evaluation of the Kansas city cardiomyopathy questionnaire: a new health status measure for heart failure[J]. J Am Coll Cardiol, 2000, 35: 1245-1255.
20. Zuluaga M C, Guallar-Castillon P, Lopez-Garcia E, et al. Generic and disease-specific quality of life as a predictor of long-term mortality in heart failure[J]. Eur J Heart Fail, 2010, 12: 1372-1378.
21. Silver M A, Maisel A, Yancy C W, et al. BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases[J]. Congest Heart Fail, 2004, 10: 1-30.
22. Gustafsson F, Steensgaard-Hansen F, Badskjaer J, et al. Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure[J]. J Card Fail, 2005, 11: S15-S20.
23. Masson S, Latini R, Anand I S, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the valsartan heart failure (Val-HeFT) data[J]. Clin Chem, 2006, 52: 1528-1538.
24. Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure[J]. Circ Heart Fail, 2011, 4: 180-187.
25. Lok D J, Van Der Meer P, de la Porte P W, et al. Prognostic-value of galectin-3, a novel marker of fibrosis, in patients withchronic heart failure: data from the DEAL-HF study[J]. Clin Res Cardiol, 2010, 99: 323-328.
26. Palerna S, Parrinello G, Cannizzaro S, et al. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure[J]. Am J Cardiol, 2009, 103: 93-102.
27. McMurray J J, Adamopoulos S, Anker S D, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J, 2012, 33: 1787-1847.
28. Sullivan M J, Hawthorne M H. Nonpharmacologic interventions in the treatment of heart failure[J]. J Cardiovasc Nurs, 1996, 10: 47-57.
29. Faris H, Flalher M, Purcell H, et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials[J]. Int J Cardiol, 2002, 82: 149-158.
30. Krum H, Cameron P. Diuretics in the treatment of heart failure: mainstay of therapy or potential hazard?[J]. J Card Fail, 2006, 12: 333-335.
31. Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north Scandinavian enalapril survival study (CONSENSUS)[J]. Am J Cardiol, 1988, 62: 60A-66A.
32. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators[J]. N Engl J Med, 1991, 325: 293-302.
33. Pfeffer M A, Braunwald E, Moye L A, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators[J]. N Engl J Med, 1992, 327: 669-677.
34. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators[J]. Lancet, 1993, 342: 821-828.
35. Bakris G L, Weir M R. Angiotensin-converling enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?[J]. Arch Intern Med, 2000, 160: 685-693.
36. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology[J]. Eur Heart J, 2005, 26: 1115-1140.
37. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial[J]. Lancet, 1999, 353: 9-13.
38. Packer M, Fowler M B, Roecker E B, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study[J]. Circulation, 2002, 106: 2194-2199.
39. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL mandomised intervention trial in congestive heart failure (MERIT-HF)[J]. Lancet, 1999, 353: 2001-2007.
40. Kendall M J, Lynch K P, Hjalmarson A, et al. Beta-blockers and sudden cardiac death[J]. Ann Intern Med, 1995, 123: 358-367.
41. Pitt B, Zannad F, Remme W J, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study lnvestigators[J]. N Engl J Med, 1999, 341: 709-717.
42. Pitt B, Remme W, Zannacl F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction[J]. N Engl J Med, 2003, 348: 1309-1321.
43. Zannad F, McMurray J J, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms[J]. N Engl J Med, 2011, 364: 11-21.
44. Konstam M A, Neaton J D, Poole-Wilson P A, et al. Lompanson of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II)[J]. Am Heart J, 2005, 150: 123-131.
45. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan[J]. Lancet, 2002, 360: 752-760.
46. Granger C B, McMurray J J, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial[J]. Lancet, 2003, 362: 772-776.
47. Cohn J N. Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in heart failure trial[J]. Cardiology, 1999, 91 Suppl 1: 19-22.
48. McMurray J J, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial[J]. Lancet, 2003, 362: 767-771.
49. Konstam M A, Neaton J D, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial[J]. Lancet, 2009, 374: 1840-1848.
50. Uretsky B F, Young J B, Shahidi F E, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group[J]. J Am Coll Cardiol, 1993, 22: 955-962.
51. Rich M W, McSherry F, Williford W O, el al. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study[J]. J Am Coll Cardiol, 2001, 38: 806-813.
52. Packer M, Gheorghiade M, Young J B, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE study[J]. N Engl J Med, 1993, 329: 1-7.
53. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study[J]. Lancet, 2010, 376: 875-885.
54. Willenheimer R, van Veldhuisen D J, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized cardiac insufficiency bisoprolol study (OBIS) III[J]. Circulation, 2005, 112: 2426-2435.
55. McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the valsartan in acute myocardialinfarction trial (VALIANT)[J]. J Am Coll Cardiol, 2006, 47: 726-733.
56. Mann J F, Schmieder R E, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial[J]. Lancet, 2008, 372: 547-553.
57. Taylor A L, Ziesche S, Yancy C, et al. Combination ofisosorbide dinitrate and hydralazine in blacks with heart failure[J]. N Engl J Med, 2004, 351: 2049-2057.
58. Li X, Zhang J, Huang J, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure[J]. J Am Coll Cardiol, 2013, 62: 1065-1072.
59. Tavazzi L, Maggioni A P, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2008, 372: 1223-1230.
60. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico[J]. Lancet, 1999, 354: 447-455.
61. Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction[J]. Circulation, 2010, 122: 2152-2159.
62. Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure[J]. J Am Coll Cardiol, 2006, 48: 992-998.
63. Fotino A D, Thompson-Paul A M, Bazzano L A. Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis[J]. Am J Clin Nutr, 2013, 97: 268-275.
64. Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration[J]. Am Heart J, 2000, 139: S120-S123.
65. Zhang L, Lu Y, Jiang H, et al. Additional use of trimetazidine in patients with chronic heart failurea meta-analysis[J]. J Am Coll Cardiol, 2012, 59: 913-922.
66. Gheorghiade M, Bohm M, Greene S J, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial[J]. JAMA, 2013, 309: 1125-1135.
67. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvaslatin in older patients with systolic heart failure[J]. N Engl J Med, 2007, 357: 2248-2261.
68. Tavazzi L, Maggioni A P, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2008, 372: 1231-1239.
69. Packer M, O'Connor C M, Ghali J K, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group[J]. N Engl J Med, 1996, 335: 1107-1114.
70. Cohn J N, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group[J]. Circulation, 1997, 96: 856-863.
71. Cleland J G, Daubert J C, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure[J]. N Engl J Med, 2005, 352: 1539-1549.
72. Bristow M R, Feldman A M, Saxon L A. Heart failure management using implantable devices for ventricular resynchronization: comparison of medical therapy, pacing, and defibrillation in chronic heart failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators[J]. J Card Fail, 2000, 6: 276-285.
73. Moss A J, Hall W J, Cannom D S, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events[J]. N Engl J Med, 2009, 361: 1329-1338.
74. Daubert C, Gold M R, Abraham W T, et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (resynchronization reverses remodeling in systolic left ventricular dysfunction) trial[J]. J Am Coll Cardiol, 2009, 54: 1837-1846.
75. Tang A S, Wells G A, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure[J]. N Engl J Med, 2010, 363: 2385-2395.
76. Lubitz S A, Leong-Sit P, Fine N, et al. Effectiveness of cardiac-resynchronization therapy in mild congestive heart failure: systematic review and meta-analysis of randomized trials[J]. Eur J Heart Fail, 2010, 12: 360-366.
77. Curtis A B, Worley S J, Adamson P B, et al. Biventricular pacing for atrioventricular block and systolic dysfunction[J]. N Engl J Med, 2013, 368: 1585-1593.
78. Ruschitzka F, Abraham W T, Singh J P, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex[J]. N Engl J Med, 2013, 369: 1395-1405.
79. Greenberg H, Case R B, Moss A J, et al. Analysis of mortality events in the multicenter automatic defibrillator implantation trial (MADIT-II)[J]. J Am Coll Cardiol, 2004, 43: 1459-1465.
80. HohnloserS H, Kuck K H, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction[J]. N Engl J Med, 2004, 351: 2481-2488.
81. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction[J]. N Engl J Med, 2009, 361: 1427-1436.
82. Kadish A, Dyer A, Daubert J P, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy[J]. N Engl J Med, 2004, 350: 2151-2158.
83. Arnold J M, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management[J]. Can J Cardiol, 2006, 22: 2345.
84. Paulus W J, Tschope C, Sanderson J E, el al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology[J]. Eur Heart J, 2007, 28: 2539-2550.
85. Cleland J G, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study[J]. Eur Heart J, 2006, 27: 2338-2345.
86. Yusuf S, PfefferM A, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial[J]. Lancet, 2003, 362: 777-781.
87. Massie B M, Carson P E, McMurray J J, et al. Irbesartan in patients with heart failure and preserved ejection fraction[J]. N Engl J Med, 2008, 359: 2456-2467.
88. Yamamoto K, Origasa H, Hori M. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese diastolic heart failure study (J-DHF)[J]. Eur J Heart Fail, 2013, 15: 110-118.
89. Solomon S D, Janardhanan R, Verma A, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial[J]. Lancet, 2007, 369: 2079-2087.
90. Reynolds H R, Hochman J S. Cardiogenic shock: current concepts and improving outcomes[J]. Circulation, 2008, 117: 686-697.
91. Hochman J S, Buller C E, Sleeper L A, et al. Cardiogenic shock complicating acute myocardial infarction-etiologies, managementand outcome: a report from the SHOCK trial registry. Should we emergently revascularize occluded coronaries for cardiogenic shock?[J]. J Am Coll Cardiol, 2000, 36: 1063-1070.
92. Januzzi J L, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing lor diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the international collaborative of NT-proBNP study[J]. Eur Heart J, 2006, 27: 330-337.
93. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (biomarkers in acute heart failure) trial[J]. J Am Coll Cardiol, 2010, 55: 2062-2076.
94. Manzano-Fernundez S, Mueller T, Pascual-Figal D, et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction[J]. Am J Cardiol, 2011, 107: 259-267.
95. Januzzi J L Jr, Peacock W F, Maisel A S, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (pro-brain natriuretic peptide investigation of dyspnea in the emergency department) study[J]. J Am Coll Cardiol, 2007, 50: 607-613.
96. Tang W H, Shrestha K, Shao Z, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival[J]. Am J Cardiol, 2011, 108: 385-390.
97. Forrester J S, Diamond G A, Swan H J. Correlative classification of clinical and hemodynamic function after acute myocardial infarction[J]. Am J Cardiol, 1977, 39: 137-145.
98. Nieminen M S, Brulsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population[J]. Eur Heart J, 2006, 27: 2725-2736.
99. Elkayam U, Janmohamed M, Habib M, et al. Vasodilators in the management of acute heart failure[J]. Crit Care Med, 2008, 36: S95-S105.
100. Amin A. Hospitalized patients with acute decompensated heart failure: recognition, risk stratification, and treatment review[J]. J Hosp Med, 2008, 3: S16-S24.
101. Felker C M, Fee K F, Bull D A, et al. Diuretic strategies in patients with acute decompensated heart failure[J]. IN Engl J Med, 2011, 364: 797-805.
102. Konslam M A, Cheorghiade M, Burnett J C Jr, et al. Effects of oral tolvaplan in patients hospitalized for worsening heart failure: the EVEREST outcome trial[J]. JAMA, 2007, 297: 1319-1331.
103. McKelvie R S, Moe G W, Ezekowitz J A, et al. The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure[J]. Can J Cardiol, 2013, 29: 168-181.
104. Chen H H, Anstrom K J, Giverlz M M, et al. Fow-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial[J]. JAMA, 2013, 310: 2533-2543.
105. Publication Committee for the VMAG Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial[J]. JAMA, 2002, 287: 1531-1540.
106. Yancy C W, Singh A. Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the follow-up serial infusions of nesiritide[FUSION I] trial)[J]. Am J Cardiol, 2006, 98: 226-229.
107. Yancy G W, Krum H, Massie B M, et al. The second follow-up serial infusions of nesiritide (FUSION II) trial for advanced heart failure: study rationale and design[J]. Am Heart J, 2007, 153: 478-484.
108. Abraham W T, Cheng M L, Smoluk G. Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers[J]. Congest Heart Fail, 2005, 11: 59-64.
109. Peacock W F 4th, Holland R, Gyarmathy R, et al. Observation unit treatment of heart failure with nesiritide: results from the proaction trial[J]. J Emerg Med, 2005, 29: 243-252.
110. O'Connor C M, Starling R C, Hernandez A F, et al. Effect of nesiritide in patients with acute decompensated heart failure[J]. N Engl J Med, 2011, 365: 32-43.
111. Teerlink J R, Cotter G, Davison B A, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial[J]. Lancet, 2013, 381: 29-39.
112. Cuffe M S, Califf R M, Adams K F Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure[J]. JAMA, 2002, 287: 1541-1547.
113. 2012, 40: 153-156.
114. Mebazaa A, Nieminen M S, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial[J]. JAMA, 2007, 297: 1883-1891.
115. Gray A, Goodacre S, Newby D E, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema[J]. N Engl J Med, 2008, 359: 142-151.
116. Costanzo M R, Guglin M E, Saltzberg M T, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure[J]. J Am Coll Cardiol, 2007, 49: 675-683.
117. Bart B A, Goldsmith S R, Lee K L, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome[J]. N Engl J Med, 2012, 367: 2296-2304.
118. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure[J]. N Engl J Med, 2008, 358: 2667-2677.
119. Bonow R O, Carabello B A, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
120. Bonow R O, Carabello B A, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
121. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012)[J]. Eur Heart J, 2012, 33: 2451-2496.
122. Makkar R R, Fontana G P, Jilaihawi H, et al. Transeatheter aortic-valve replacement for inoperable severe aortic stenosis[J]. N Engl J Med, 2012, 366: 1696-1704.
123. Velazquez E J, Lee K L, Deja M A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction[J]. N Engl J Med, 2011, 364: 1607-1616.
124. Jones R H, Velazquez E J, Michler R E, et al. Coronary bypass surgery with or without surgical ventricular reconstruction[J]. N Engl J Med, 2009, 360: 1705-1717.
125. Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis[J]. J Am Coll Cardiol, 2012, 59: 779-792.
126. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)[J]. Eur Heart J, 2008, 29: 2388-2442.
127. Hawkins N M, Petrie M C, Macdonald M R, et al. Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists[J]. J Am Coll Cardiol, 2011, 57: 2127-2138.
128. Kotlyar E, Keogh A M, Macdonald P S, et al. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma[J]. J Heart Lung Transplant, 2002, 21: 1290-1295.
129. Le Jemtel T H, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure[J]. J Am Coll Cardiol, 2007, 49: 171-180.
130. Mancini D M, Katz S D, Lang C C, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure[J]. Circulation, 2003, 107: 294-299.
131. Bolger A P, Bartlett F R, Penston H S, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure[J]. J Am Coll Cardiol, 2006, 48: 1225-1227.
132. Swedberg K, Young J B, Anand I S, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure[J]. N Engl J Med, 2013, 368: 1210-1219.
133. 2012, 40: 449-461.
134. Howlell J G, McKelvie R S, Arnold J M, et al. Canadian Cardiovascular Society consensus conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials[J]. Can J Cardiol, 2009, 25: 85-105.
135. Haddad F, Doyle R, Murphy D J, et al. Right ventricular function in cardiovascular disease, part H: pathophysiology, clinical importance, and management of right ventricular failure[J]. Circulation, 2008, 117: 1717-1731.
136. McLaughlin V V, Archer S L, Badesch D B, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association[J]. Circulation, 2009, 119: 2250-2294.
137. Badesch D B, Abman S H, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines[J]. Chest, 2007, 131: 1917-1928.
138. Galie N, Hoeper M M, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)[J]. Eur Heart J, 2009, 30: 2493-2537.
139. Jaff M R, McMurtry M S, Archer S L, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association[J]. Circulation, 2011, 123: 1788-1830.
140. O'Connor C M, Whellan D J, Lee K L, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial[J]. JAMA, 2009, 301: 1439-1450.
141. Sochalski J, Jaarsma T, Krumholz H M, et al. What works in chronic care management: the case of heart failure[J]. Health Aff (Millwood), 2009, 28: 179-189.
142. Jaarsma T, Beattie J M, Ryder M, et al. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2009, 11: 433-443.
143. van Veldhuisen D J, Braunschweig F, Conraads V, et al. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure[J]. Circulation, 2011, 124: 1719-1726.
144. Catanzariti D, Lunati M, Landolina M, et al. Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure[J]. Pacing Clin Electrophysiol, 2009, 32: 363-370.
145. Anker S D, Koehler F, Abraham W T. Telemedicine and remote management of patients with heart failure[J]. Lancet, 2011, 378: 731-739.
146. Chaudhry S I, Mattera J A, Curtis J P, et al. Telemonitoring in patients with heart failure[J]. N Engl J Med, 2010, 363: 2301-2309.